Danaher Corporation
DHR
$218.85
+1.36%
Danaher Corporation is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and commercial products and services, with a primary focus on life sciences and diagnostics. As a market leader in the healthcare technology sector, Danaher distinguishes itself through its Danaher Business System (DBS), a continuous improvement framework that drives operational excellence and successful M&A integration. The current investor narrative centers on the company's post-Veralto divestiture transformation, its strategic acquisition of Masimo (announced in early 2026), and the recovery of its bioprocessing segment, which has been a key driver of recent stock volatility and growth expectations.…
DHR
Danaher Corporation
$218.85
Related headlines
Investment Opinion: Should I buy DHR Today?
Based on the analysis, DHR is rated a Buy. The thesis is that the company's transformation, including the Masimo acquisition and bioprocessing recovery, will drive earnings growth that justifies the forward valuation. The analyst consensus is Strong Buy with an average target of $227.96, implying 4.2% upside. Key supporting data points include the forward PE of 23.5x, which is near the industry average, the 3.7% revenue growth, and the strong gross margin of 60.9%. The company also generates robust free cash flow of $5.29 billion, supporting continued investment and M&A.
Sign up to view all
DHR 12-Month Price Forecast
The AI assessment is cautiously bullish, as the forward valuation is reasonable and the company has a strong market position. However, the moderate growth rate and wide analyst target range introduce uncertainty. The stance would be upgraded to high confidence if revenue growth accelerates above 5% and the Masimo acquisition shows clear synergies. Conversely, a downgrade to neutral would occur if growth decelerates or integration issues emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Danaher Corporation's 12-month outlook, with a consensus price target around $227.96 and implied upside of +4.2% versus the current price.
Average Target
$227.96
0 analysts
Implied Upside
+4.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$195 - $310
Analyst target range
The target price range spans from $195 to $310, a wide spread of $115, which highlights significant uncertainty about Danaher's future performance. The high target assumes that the Masimo acquisition will be accretive and that the bioprocessing segment will return to double-digit growth, leading to multiple expansion. The low target, on the other hand, prices in potential integration challenges, competitive pressures, or a slowdown in healthcare spending. Recent institutional ratings show a mix of actions, including a downgrade from Citigroup (from Buy to Neutral) and an upgrade from HSBC (to Buy), indicating that sentiment is not uniformly bullish. The wide range and mixed recent actions suggest that while the consensus is positive, there is meaningful debate about the pace and magnitude of the company's recovery.
Bulls vs Bears: DHR Investment Factors
Danaher presents a balanced but slightly bullish case. The bull case is supported by strong recent momentum, a reasonable forward valuation, and a solid balance sheet, while the bear case highlights the high trailing PE, moderate growth, and analyst uncertainty. The most important tension is whether the bioprocessing recovery and Masimo acquisition will deliver the earnings growth implied by the forward PE. If they do, the stock could re-rate higher; if not, the premium valuation could compress. Currently, the evidence slightly favors the bulls, given the strong operational execution and strategic positioning, but the wide target range and mixed analyst actions warrant caution.
Bullish
- Strong Momentum with 27.2% 3-Month Surge: DHR has rallied 27.2% over the last three months, closing at $218.85, near the top of its 52-week range. This momentum reflects renewed investor confidence in the bioprocessing recovery and the Masimo acquisition, suggesting the market is pricing in a successful transformation.
- Forward PE at 23.5x Aligns with Sector: The forward PE of 23.5x is only 7% above the industry average of 22x, indicating that the market's growth expectations are reasonable. This contrasts with the trailing PE of 45.2x, which is distorted by depressed earnings, and suggests the stock is not excessively priced relative to future earnings.
- Recurring Revenue Provides Stability: Recurring revenue of $5.031 billion accounts for 84.5% of total revenue, providing a predictable base. This recurring stream supports stable cash flows and reduces earnings volatility, a key strength in a healthcare technology business.
- Analyst Consensus is Strong Buy: With 23 analysts, the consensus rating is 'Strong Buy' and the average target price is $227.96, implying 4.2% upside from the current price. The high target of $310 suggests significant upside potential if the Masimo acquisition and bioprocessing recovery exceed expectations.
Bearish
- Trailing PE at 45.2x Signals Overvaluation: The trailing PE of 45.2x is more than double the industry average of 22x, reflecting that current earnings are depressed. If earnings growth does not materialize as expected, the stock could face significant multiple compression.
- Wide Analyst Target Range Indicates Uncertainty: The analyst target range spans from $195 to $310, a 59% spread, highlighting substantial disagreement about the company's future. This uncertainty could lead to volatility if results deviate from expectations.
- Recent Downgrade from Citigroup: Citigroup downgraded DHR from Buy to Neutral, reflecting concerns about integration risks and the pace of recovery. This mixed sentiment suggests not all analysts are convinced of the bullish thesis.
- Revenue Growth Remains Moderate at 3.7%: Q1 2026 revenue grew only 3.7% YoY, below the double-digit growth seen in earlier years. This moderate growth may not justify the premium valuation if it does not accelerate.
DHR Technical Analysis
Danaher's stock is currently in a strong recovery phase, having rebounded significantly from its 52-week low of $160.93. Over the past year, the stock has gained 7.3%, but the more telling move is the 27.2% surge over the last three months, which has propelled the price to $218.85, near the upper end of its 52-week range (currently at 90% of the range). This positioning suggests strong momentum and renewed investor confidence, though it also raises the risk of short-term overextension. The stock's beta of 0.80 indicates it is less volatile than the broader market, providing some cushion in turbulent times.
Beta
0.80
0.80x market volatility
Max Drawdown
-33.1%
Largest decline past year
52-Week Range
$161-$243
Price range past year
Annual Return
+7.3%
Cumulative gain past year
| Period | DHR Return | S&P 500 |
|---|---|---|
| 1m | +22.2% | +3.6% |
| 3m | +27.2% | +2.7% |
| 6m | +4.5% | +11.4% |
| 1y | +7.3% | +18.7% |
| ytd | -5.0% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DHR Fundamental Analysis
Danaher's revenue trajectory shows steady growth, with the most recent quarter (Q1 2026) reporting revenue of $5.951 billion, a 3.7% year-over-year increase. This growth is consistent with the prior quarter's $6.838 billion (Q4 2025), which represented a 4.6% increase from the year-ago period, indicating a stable, albeit moderate, expansion. The company's recurring revenue segment, which accounts for $5.031 billion of total revenue, provides a solid base, while non-recurring revenue of $0.92 billion adds incremental upside. The growth is primarily driven by the life sciences and diagnostics segments, which have benefited from increased demand for bioprocessing and diagnostic tools, though the pace remains below the double-digit growth seen in earlier years.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+3.7%
YoY Comparison
Gross Margin
60.3%
Latest Quarter
Free Cash Flow
$5.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DHR Overvalued?
Given Danaher's positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE stands at 45.2x, while the forward PE is 23.5x, implying that the market expects significant earnings growth over the next year. This gap suggests that investors are pricing in a strong recovery in profitability, likely driven by margin expansion and the Masimo acquisition. Compared to the industry average PE of 22x, Danaher trades at a 105% premium on a trailing basis, but on a forward basis, the premium narrows to just 7%, indicating that the market's growth expectations are largely aligned with the sector.
PE
45.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include the high trailing PE of 45.2x, which implies that the market expects significant earnings growth. If the bioprocessing recovery stalls or the Masimo integration underperforms, earnings could disappoint, leading to multiple compression. The company's debt-to-equity ratio is low at 0.35, but the acquisition of Masimo may increase leverage, and the integration costs could pressure margins. Additionally, the payout ratio of 24.3% and dividend yield of 0.54% indicate a modest return to shareholders, which may not attract income-focused investors.
FAQ
Key risks include: 1) Integration risk from the Masimo acquisition, which could lead to cost overruns and management distraction. 2) The bioprocessing segment may not recover as quickly as expected, leading to lower growth. 3) The high trailing PE leaves little room for error; any earnings miss could trigger a sell-off. 4) Healthcare policy changes could impact demand for diagnostics and life sciences tools.
The 12-month forecast is moderately bullish. The base case, with a 50% probability, targets $210-$240, aligning with the analyst average of $227.96. The bull case, with 30% probability, targets $240-$310, while the bear case, with 20% probability, targets $160-$195. The most likely scenario is moderate growth, with the stock trading near current levels.
On a trailing basis, DHR is overvalued with a PE of 45.2x, but on a forward basis, it is fairly valued with a PE of 23.5x, close to the industry average of 22x. The market is pricing in significant earnings growth, which is expected from the bioprocessing recovery and Masimo acquisition. If these expectations are met, the valuation is justified; otherwise, the stock could be overvalued.
DHR is a good buy for investors with a long-term horizon, given its strong market position and reasonable forward valuation. The analyst consensus is Strong Buy with an average target of $227.96, implying 4.2% upside. However, the trailing PE of 45.2x is high, and the stock could be volatile in the short term. It is best suited for investors who believe in the bioprocessing recovery and the Masimo acquisition.
DHR is more suitable for long-term investment due to its growth trajectory and strategic acquisitions. The stock has a beta of 0.80, indicating lower volatility than the market, but it can still experience significant swings. The dividend yield is low at 0.54%, so income is not a primary benefit. A minimum holding period of 3-5 years is recommended to allow the bioprocessing recovery and Masimo integration to play out.